GlassScriptPhysician profile
Yvette L Guislain
NPI 1669477220
$4,221.22
in general payments reported to CMS, 2019-2025
38 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $245 · 2021: $162 · 2022: $800 · 2023: $568 · 2024: $870 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809 · Education: $56.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.26 |
| Education | $56.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.06 | 2022-2025 | Ubrelvy, Vraylar, Synthroid |
| Pfizer INC. | $332.47 | 2022-2025 | |
| Glaxosmithkline, LLC. | $328.51 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $253.63 | 2022-2023 | |
| Sonex Health, INC. | $251.38 | 2025 | Sx-One Microknife |
| Amarin Pharma, INC. | $247.99 | 2019-2020 | |
| Novo Nordisk INC | $246.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $230.65 | 2022-2025 | Jardiance, Kisunla, Emgality |
| Shield Therapeutics INC | $213.62 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $188.44 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Abbott Laboratories | $176.70 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $135.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Nevro Corp. | $130.53 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $116.52 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $116.03 | 2022-2025 | Airsupra, Breztri |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Guislain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.